Immunotherapy: reshape the tumor immune microenvironment
B Lv, Y Wang, D Ma, W Cheng, J Liu, T Yong… - Frontiers in …, 2022 - frontiersin.org
Tumor immune microenvironment (TIME) include tumor cells, immune cells, cytokines, etc.
The interactions between these components, which are divided into anti-tumor and pro …
The interactions between these components, which are divided into anti-tumor and pro …
[HTML][HTML] LAG-3: from molecular functions to clinical applications
T Maruhashi, D Sugiura, I Okazaki… - … for immunotherapy of …, 2020 - ncbi.nlm.nih.gov
To prevent the destruction of tissues owing to excessive and/or inappropriate immune
responses, immune cells are under strict check by various regulatory mechanisms at …
responses, immune cells are under strict check by various regulatory mechanisms at …
The PD-1-and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial
JJ Luke, MR Patel, GR Blumenschein, E Hamilton… - Nature medicine, 2023 - nature.com
Tebotelimab, a bispecific PD-1× LAG-3 DART molecule that blocks both PD-1 and LAG-3,
was investigated for clinical safety and activity in a phase 1 dose-escalation and cohort …
was investigated for clinical safety and activity in a phase 1 dose-escalation and cohort …
Immunotherapy in colorectal cancer: rationale, challenges and potential
Following initial successes in melanoma treatment, immunotherapy has rapidly become
established as a major treatment modality for multiple types of solid cancers, including a …
established as a major treatment modality for multiple types of solid cancers, including a …
Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia
Tolerance to self-antigens prevents the elimination of cancer by the immune system,. We
used synthetic chimeric antigen receptors (CARs) to overcome immunological tolerance and …
used synthetic chimeric antigen receptors (CARs) to overcome immunological tolerance and …
LAG3 associates with TCR–CD3 complexes and suppresses signaling by driving co-receptor–Lck dissociation
LAG3 is an inhibitory receptor that is highly expressed on exhausted T cells. Although LAG3-
targeting immunotherapeutics are currently in clinical trials, how LAG3 inhibits T cell function …
targeting immunotherapeutics are currently in clinical trials, how LAG3 inhibits T cell function …
[HTML][HTML] Fibrinogen-like protein 1 is a major immune inhibitory ligand of LAG-3
Summary Lymphocyte-activation gene 3 (LAG-3) is an immune inhibitory receptor, with
major histocompatibility complex class II (MHC-II) as a canonical ligand. However, it remains …
major histocompatibility complex class II (MHC-II) as a canonical ligand. However, it remains …
Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo
The efficacy of chimeric antigen receptor (CAR) T cell therapy against poorly responding
tumors can be enhanced by administering the cells in combination with immune checkpoint …
tumors can be enhanced by administering the cells in combination with immune checkpoint …
The promising immune checkpoint LAG-3 in cancer immunotherapy: from basic research to clinical application
JL Huo, YT Wang, WJ Fu, N Lu, ZS Liu - Frontiers in immunology, 2022 - frontiersin.org
LAG-3, a type of immune checkpoint receptor protein belonging to the immunoglobulin
superfamily, is confirmed to be expressed on activated immune cells, mainly including …
superfamily, is confirmed to be expressed on activated immune cells, mainly including …
Safety and efficacy of nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: results from the phase I/II CheckMate 358 trial
PURPOSE Nivolumab was assessed in patients with virus-associated tumors in the phase
I/II CheckMate 358 trial (ClinicalTrials. gov identifier: NCT02488759). We report on patients …
I/II CheckMate 358 trial (ClinicalTrials. gov identifier: NCT02488759). We report on patients …